Quick Answer
Syndax Pharmaceuticals Inc reported Research And Development Expense of $258.78 million for the year ending 2025.
- Syndax Pharmaceuticals Inc showed an increase of +7.1% in Research And Development Expense from 2024 to 2025.
- This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $1.72 million | Q2 2015: $2.27 million | Q3 2015: $2.97 million | Q4 2015: $2.59 million | Q1 2016: $4.79 million | Q2 2016: $6.13 million | Q3 2016: $12.27 million | Q4 2016: $8.47 million | Q1 2017: $9.55 million | Q2 2017: $9.86 million | Q3 2017: $12.19 million | Q4 2017: $16.60 million | Q1 2018: $15.34 million | Q2 2018: $14.85 million | Q3 2018: $14.10 million | Q4 2018: $15.82 million | Q1 2019: $11.28 million | Q2 2019: $12.29 million | Q3 2019: $9.92 million | Q4 2019: $9.50 million | Q1 2020: $9.56 million | Q2 2020: $10.94 million | Q3 2020: $14.41 million | Q4 2020: $15.52 million | Q1 2021: $21.87 million | Q2 2021: $16.87 million | Q3 2021: $25.61 million | Q1 2022: $30.02 million | Q2 2022: $29.73 million | Q3 2022: $26.90 million | Q1 2023: $34.05 million | Q2 2023: $34.76 million | Q3 2023: $39.09 million | Q1 2024: $56.49 million | Q2 2024: $48.66 million | Q3 2024: $70.97 million | Q1 2025: $61.64 million | Q2 2025: $62.23 million | Q3 2025: $56.28 million.
- Over the full 12 years of available data (2014 to 2025), Syndax Pharmaceuticals Inc's Research And Development Expense has grown by 2,443.3%.
- Historical annual values: Fiscal year 2025: $258.78 million | Fiscal year 2024: $241.65 million | Fiscal year 2023: $163.03 million | Fiscal year 2022: $118.50 million | Fiscal year 2021: $88.25 million | Fiscal year 2020: $50.44 million | Fiscal year 2019: $42.99 million | Fiscal year 2018: $60.11 million | Fiscal year 2017: $48.20 million | Fiscal year 2016: $31.67 million | Fiscal year 2015: $9.55 million | Fiscal year 2014: $10.18 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: